Skip to content
Published studies and FDA documents are linked throughout.
Doctor CJC-1295

CJC-1295 findings set down carefully. No practice runs here.

Menu
Three adults with towels over their shoulders walking along a pool deck toward the changing rooms, seen from behind

CJC-1295 research in people

Small studies established a lasting hormone response. They did not establish a lasting health benefit.

The form behind the findings

The name CJC-1295 needs a qualifier before a study result becomes useful. The published human work concerns the long-acting form with DAC, short for Drug Affinity Complex. This addition allows the peptide to bind albumin in blood. The resulting exposure differs from the substance commonly described as CJC-1295 without DAC.

FDA's 2024 evaluation found no human study of the no-DAC form. It also described inconsistent names for related ingredients. A paper about one form cannot establish the duration, dose, or safety of another. Adding ipamorelin changes the question again: a combination needs evidence for the combination, rather than a sum of findings about its parts.

The first development paper by Jetté and colleagues in 2005 involved rats and laboratory tests. It helped explain albumin binding and the longer response. That work supplied a reason to study the compound in people; it did not supply evidence of a human treatment benefit.

The 2006 hormone study

Teichman and colleagues reported sustained growth hormone and IGF-1 changes in healthy adults in 2006. After a single administration, mean growth hormone rose twofold to tenfold for at least six days. IGF-1 rose about 1.5-fold to threefold for nine to eleven days. The estimated drug half-life was 5.8–8.1 days.

Those numbers describe the study's biological measurements. They are not targets for a reader's hormone levels. The participants were healthy adults, and the study was designed around pharmacology and short-term safety. It did not demonstrate improved sleep, increased muscle, reduced body fat, or slower aging.

Half-life describes how slowly the amount of a substance falls in the body. It does not tell a prescriber how often an unapproved compound can safely be administered. The dosage discussion keeps the research amounts separate from personal treatment decisions.

Growth hormone pulses continued

Growth hormone normally rises and falls rather than remaining at one level. Ionescu and Frohman studied whether this pattern continued during exposure to long-acting CJC-1295. Their 2006 report found that pulses persisted even as background hormone concentrations increased.

That finding narrows one concern about continuous stimulation. It does not prove that every aspect of hormone regulation stayed normal, or that a larger average signal was helpful. It also does not settle what happens after months of exposure or when another peptide is added.

A 2009 report by Sackmann-Sala and colleagues examined blood from eleven healthy men. It found changes in serum protein patterns associated with hormone-system activation. These were candidate biological markers, not evidence that participants felt or functioned better.

The trial that did not produce published results

A later trial studied CJC-1295 in people with HIV and excess abdominal fat. The ClinicalTrials.gov record marks that study as terminated. Results were not posted there. Its planned population and clinical purpose differ from the earlier healthy-volunteer work.

FDA's review recounts anecdotal reports of a participant's death during development. The available account does not establish whether CJC-1295 caused the event, and it does not rule out a contribution. Unpublished results cannot be treated as either a successful trial or a reliable estimate of risk.

What the record still cannot answer

The central gap is clinical benefit. Changing growth hormone or IGF-1 is measurable, but a useful therapy must improve an outcome that matters and have an acceptable safety profile. The small published studies did not answer that broader question.

Long-term safety, effects in children, and pregnancy safety remain unresolved. The fixed CJC-1295/ipamorelin blend has no controlled human trial establishing its benefits. No-DAC claims also lack the human evidence available for the DAC form. The effects page describes the adverse findings and the concerns that follow from the hormone pathway, with those evidence types kept distinct.

Continue reading

Effects and safety